Recently there has been great interest in brain tumor therapies that suppress growth factors generated by cancer cells for the generation of new blood vessels (angiogenesis). However, while frequently successful in the short term, all current anti- angiogenic therapies eventually fail. This failure has been attributed to invasive cancer cell growth along existing normal vasculature, termed vessel co-option. Indeed, anti- angiogenic therapies in rodent brain tumor models have recently been shown to accelerate tumor invasion by vessel co-option, leading to escape from anti-angiogenic therapy. New combination therapies that target both tumor angiogenesis and invasion are therefore urgently needed. However, detecting invasive tumor regions and assessing their response to potential therapies is complicated by the lack of methods for detecting such invasive cancer cells. Conventional Magnetic Resonance Imaging (MRI) methods detect the elevated vascular permeability and edema that are characteristic of angiogenesis driven tumor growth. Invasive cancer cells that co-opt normal vasculature, however, do not display elevated permeability or edema, thereby rendering them invisible to MRI. New methods are therefore urgently needed for detecting such invasive tumor regions. We propose to investigate and validate the use of novel MRI vascular biomarkers that are sensitive to vascular changes induced by invasive cancer cells in the absence of angiogenesis and its associated elevated edema and vascular permeability. We will also investigate the sensitivity of these new MRI biomarkers to changes induced by anti- tumor therapy. These studies will be performed in invasive mouse brain tumor models that closely mimic tumor growth patterns observed clinically. We hypothesize that these novel MRI vascular biomarkers will provide highly sensitive measures of vascular changes and vessel co-option in invasive brain tumor regions that are not detectable by current methods.

Public Health Relevance

No clinical methods are currently available for the detection of invasive tumor regions that grow by vessel co-option. The development of MRI biomarkers of tumor invasion is therefore critical for (1) the detection of invasive tumor borders, thereby improving tumor resection, (2) the detection of escape from anti-angiogenic therapy, and (3) monitoring the response of invasive cancer cells to new tumor therapies that target both tumor angiogenesis and invasion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA155862-02
Application #
8231305
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Menkens, Anne E
Project Start
2011-03-01
Project End
2013-06-30
Budget Start
2012-03-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$192,103
Indirect Cost
$83,353
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Snuderl, Matija; Batista, Ana; Kirkpatrick, Nathaniel D et al. (2013) Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152:1065-76